The Sir David Jack Memorial
Sir David Jack is to be remembered as the main driving force behind one of the UK’s – and the World’s – foremost pharmaceutical companies. He was responsible, as Research and Development Director in the late 1960s, for putting in train a series of events that would take Glaxo, and their subsidiary Allen & Hanbury, from manufacturers of ‘formula’ baby milk and cough pastilles to the highest echelons of their industry.
Many key pharmaceutical products were developed by Glaxo during Sir David Jack’s tenure of his post between 1961 and 1987. Asthma, a killer affliction in the late 1940s and 50s, became a mere inconvenience – relieved by a succession of increasingly effective treatments developed at Greenford in West London and Ware in Hertfordshire. By developing a methodology of research, the teams established an effective control of mucus-secreting cells – the main problem with asthma – without the debilitating side-effects. And thus this process was extended to other afflictions of the human body, ultimately providing GlaxoSmithKline with a platform on which to generate a portfolio of highly profitable, global products that exists and is still in development today.
When Sir Andrew Witty, CEO of GlaxoSmithKline, asked for the Ware Research site to be renamed in Sir David Jack's memory, this is what we achieved.
5 years ago